ABSTRACT
Thyroid dysfunction in pregnancy is strongly associated with adverse maternal and foetal outcomes. The effects of treatment are less clear. There is ongoing discussion on whom to treat, when to treat and whether treatment is beneficial. Although universal screening for thyroid disease during pregnancy increases diagnosis and treatment of thyroid dysfunction, there is currently insufficient evidence demonstrating a positive effect of screening on maternal and foetal outcomes. We therefore, at present, recommend against universal screening for thyroid disease before and during pregnancy.
Subject(s)
Mass Screening/methods , Pregnancy Complications/diagnosis , Thyroid Diseases/diagnosis , Female , Humans , Mass Screening/economics , Mass Screening/standards , Mass Screening/statistics & numerical data , Practice Guidelines as Topic/standards , Predictive Value of Tests , Pregnancy , Pregnancy Complications/epidemiology , Pregnancy Complications/therapy , Pregnancy Outcome/epidemiology , Prevalence , Thyroid Diseases/epidemiology , Thyroid Diseases/therapy , Thyroid Function Tests/economics , Thyroid Function Tests/methods , Thyroid Function Tests/statistics & numerical dataABSTRACT
This case report describes a female HIV-positive patient diagnosed with pelvic actinomycosis using 16S rRNA gene sequence analysis. Actinomycosis is notoriously difficult to diagnose by microbiological culture. 16S rRNA gene sequence analysis allows rapid definitive diagnosis of actinomycosis and is potentially of great value in a clinical setting. This is the first report of pelvic actinomycosis in an HIV-1 infected patient.
